XORTX reminds shareholders of voting deadline for upcoming annual and extraordinary shareholders’ meeting Page 1

CALGARY, Alberta, September 6, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical-stage pharmaceutical company focused on the development of innovative therapies for the treatment of progressive kidney disease, reminds shareholders of the upcoming deadline to vote at the Company’s annual general and extraordinary meeting (the “Meeting”), scheduled for September 12, 2024.

The Board of Directors of XORTX Recommends to Shareholders
vote FOR ALL suggested items